umu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Overview of pharmacological interventions after traumatic brain injuries: impact on selected outcomes
Umeå University, Faculty of Medicine, Department of Community Medicine and Rehabilitation.
Show others and affiliations
2019 (English)In: Brain Injury, ISSN 0269-9052, E-ISSN 1362-301X, Vol. 33, no 4, p. 442-455Article in journal (Refereed) Published
Abstract [en]

The purpose of this study was to conduct an overview of systematic reviews (SRs) to appraise the published evidence related to pharmacological interventions after traumatic brain injury (TBI). Searches were conducted with Medline, Embase, PsycINFO, Web of Science, PubMed. 780 retrieved SRs underwent a two-level screening to determine inclusion. Data extracted included participant characteristics, TBI severity, study design, pharmacological interventions, and outcomes. SRs were assessed for methodological quality by using the AMSTAR measurement tool. After removing duplicates, 166/780 SRs published between 1990-2017 were reviewed, 62 of which met inclusion criteria. More than 90 drugs and 22 substance-classes were extracted. Most medications were administered during the acute stage. Mild TBI was included in 3% of the SRs. Physiological outcomes comprised 45% of the SRs, primarily mortality. Activities of daily living (ADLs) outcomes constituted 22% of the SRs followed by cognition (13%) and psychological/behavioral outcomes (13%). Only 7% of the SRs assessed adverse events. Inconsistencies in definitions, methods, and heterogeneity of instruments used to measure treatment response were noted. Only a third of the SRs had high methodological quality. Most SRs had heterogeneous TBI samples, outcomes, or methodologies making it difficult to synthesize findings into recommended guidelines. This study demonstrated a need for adequately powered and rigorous randomized clinical trials (RCTs) to provide generalizable evidence on the effectiveness of pharmacologic interventions for TBI. PROSPERO Registration: CRD42015017355.

Place, publisher, year, edition, pages
Taylor & Francis, 2019. Vol. 33, no 4, p. 442-455
Keywords [en]
Systematic review, meta-analysis, traumatic brain injury, pharmacological interventions
National Category
Neurology
Identifiers
URN: urn:nbn:se:umu:diva-157190DOI: 10.1080/02699052.2019.1565896ISI: 000458936100007PubMedID: 30694081OAI: oai:DiVA.org:umu-157190DiVA, id: diva2:1304900
Available from: 2019-04-15 Created: 2019-04-15 Last updated: 2019-04-15Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Hu, Xiao-Lei

Search in DiVA

By author/editor
Kim, SonyaHu, Xiao-LeiKrishnan, Shilpa
By organisation
Department of Community Medicine and Rehabilitation
In the same journal
Brain Injury
Neurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 29 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf